- Home
- ZURA vs LRMR Comparison
ZURA vs LRMR Comparison
Compare ZURA & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | LRMR |
|---|---|---|
| Founded | 2022 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 252.9M | 276.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | ZURA | LRMR |
|---|---|---|
| Price | $5.17 | $3.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $11.38 | ★ $16.71 |
| AVG Volume (30 Days) | 666.0K | ★ 1.2M |
| Earning Date | 11-13-2025 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.97 | $1.61 |
| 52 Week High | $5.75 | $5.37 |
Technical Indicators
Market Signals| Indicator | ZURA | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 62.01 | 40.33 |
| Support Level | $4.75 | $3.12 |
| Resistance Level | $5.28 | $3.40 |
| Average True Range (ATR) | 0.51 | 0.17 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 61.36 | 21.86 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.